The global helicobacter pylori non-invasive testing market is projected to register at a moderate-paced CAGR of 4.4% over the forecast period. The helicobacter pylori non-invasive testing market is currently valued at US$ 650.50 Mn in 2023. By 2033, demand for helicobacter pylori non-invasive testing is expected to reach a high of US$ 1000.57 Mn.
Request Sample@ https://www.futuremarketinsights.com/reports/sample/rep-gb-15823
The growth of the helicobacter pylori non-invasive testing market is expected to be spurred by factors such as the increasing prevalence of Helicobacter pylori bacterial infection, increased governmental awareness about infection for accurate diagnosis, and the launch of new products and the approval of those products by the Food and Drug Administration. Although the demand for helicobacter pylori non-invasive testing has potential, it is unlikely to develop due to problems like a low detection rate, the absence of any outward symptoms, and stringent regulatory constraints. However, doctors have still advised patients to get treatment for H. Pylori infections as soon as feasible, despite the lack of evidence linking COVID-19 and the virus.
Market share for non-invasive testing for Helicobacter pylori (H. pylori) is highest in North America, while growth is quickest in Asia-Pacific. Due to rising rates of gastric cancer, duodenal ulcers, and gastric ulcers, as well as the improvement of healthcare infrastructure, the North American helicobacter pylori non-invasive testing market is anticipated to expand throughout the forecast period.
During the forecast period, the market for non-invasive tests for H. pylori is expected to grow at a rate greatest in Asia Pacific. China, India, and Japan are just a few of the countries in the region where the demand for helicobacter pylori non-invasive testing is anticipated to expand at a rapid rate in the future years. As the ageing population in Asia and the Pacific rises, along with the frequency of Helicobacter pylori (H. pylori) and gastric cancer cases, the market for non-invasive testing of H. pylori is projected to expand. That’s why there’s so much opportunity for development in the region throughout the predicted expansion period for helicobacter pylori non-invasive testing market players.
Ask an Analyst@ https://www.futuremarketinsights.com/ask-the-analyst/rep-gb-15823
Key Takeaways
- Demand for helicobacter pylori (H. pylori) non-invasive tests is anticipated to be driven by the rise in non-invasive testing for H. pylori diagnosis and the lack of endoscopic facilities.
- The non-invasive testing demand for helicobacter pylori (H. pylori) is expanding due to increasing government awareness of infection and the need for accurate diagnosis, rising demand for point-of-care testing equipment, and the widespread availability of diagnostics tests.
- The helicobacter pylori (H. pylori) non-invasive testing demand is anticipated to grow as a result of factors such as the increasing prevalence of H. pylori infection, the introduction of new products, and the approval of these products by the Food and Drug Administration.
- The global ageing population and the rising number of people with stomach ulcers are expected to fuel the growth of the helicobacter pylori non-invasive testing market.
- The adoption of non-invasive testing for helicobacter pylori (H. pylori) is expected to grow during the projected period due to rising technical developments and an increase in innovations.
- The demand for non-invasive tests to identify helicobacter pylori (H. pylori) is projected to face challenges such as a low detection rate, the fact that H. pylori infection often has no symptoms, and strict regulatory regulations.
Competitive Landscape
The global helicobacter pylori non-invasive testing market comprises of the following players: Meridian Bioscience, Inc., DiaSorin S.p.A, Alere, Sekiusi Diagnostics and Biomerica, Inc. Besides these, a host of other players have a significant market presence as well. These are Biohit Oyj, Exalenz Bioscience Ltd., Aalto Bio Reagents Ltd., Certest Biotec S.L. and CorisBioconcept SPRL.
Recent Developments
The FDA cleared Meridian Bioscience, Inc. to market its novel Curian and Curian HpSA assays in March of 2020. The new analyzer and initial assay are critical components of their plan to maintain market dominance in the testing of gastrointestinal diseases.
Thermo Fischer Scientific, a world-renowned provider of clinical research services to the biopharma and biotech industries, announced in December 2021 that it is expected to acquire PPD, Inc. for US$17.4 billion.
Request Customization@ https://www.futuremarketinsights.com/customization-available/rep-gb-15823
Key Segments in the Helicobacter Pylori Non-Invasive Testing Market
By Non-invasive Test Type:
- Serology Test
- Stool Antigen Test
- Urea Breath Test
By Test Type:
- Laboratory-based Tests
- Point-of-Care Tests
By End-user:
- Hospitals
- Diagnostic Labs
- Clinics
About Future Market Insights (FMI)
Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact:
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn| Twitter| Blogs